Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

1.

Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease.

Shanker V, Groves M, Heiman G, Palmese C, Saunders-Pullman R, Ozelius L, Raymond D, Bressman S.

Mov Disord. 2011 Aug 15;26(10):1875-80. doi: 10.1002/mds.23746. Epub 2011 May 24. Erratum in: Mov Disord. 2011 Dec;26(14):2586.

PMID:
21611978
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.

Alcalay RN, Mirelman A, Saunders-Pullman R, Tang MX, Mejia Santana H, Raymond D, Roos E, Orbe-Reilly M, Gurevich T, Bar Shira A, Gana Weisz M, Yasinovsky K, Zalis M, Thaler A, Deik A, Barrett MJ, Cabassa J, Groves M, Hunt AL, Lubarr N, San Luciano M, Miravite J, Palmese C, Sachdev R, Sarva H, Severt L, Shanker V, Swan MC, Soto-Valencia J, Johannes B, Ortega R, Fahn S, Cote L, Waters C, Mazzoni P, Ford B, Louis E, Levy O, Rosado L, Ruiz D, Dorovski T, Pauciulo M, Nichols W, Orr-Urtreger A, Ozelius L, Clark L, Giladi N, Bressman S, Marder KS.

Mov Disord. 2013 Dec;28(14):1966-71. doi: 10.1002/mds.25647. Epub 2013 Oct 15.

PMID:
24243757
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism.

van Nuenen BF, Helmich RC, Ferraye M, Thaler A, Hendler T, Orr-Urtreger A, Mirelman A, Bressman S, Marder KS, Giladi N, van de Warrenburg BP, Bloem BR, Toni I; LRRK2 Ashkenazi Jewish Consortium.

Brain. 2012 Dec;135(Pt 12):3687-98. doi: 10.1093/brain/aws288.

PMID:
23250886
[PubMed - indexed for MEDLINE]
Free Article
4.

Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.

Yahalom G, Kaplan N, Vituri A, Cohen OS, Inzelberg R, Kozlova E, Korczyn AD, Rosset S, Friedman E, Hassin-Baer S.

Parkinsonism Relat Disord. 2012 Nov;18(9):1039-41. doi: 10.1016/j.parkreldis.2012.05.014. Epub 2012 Jun 13.

PMID:
22703868
[PubMed - indexed for MEDLINE]
5.

The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?

Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N.

Neurology. 2007 Oct 16;69(16):1595-602.

PMID:
17938369
[PubMed - indexed for MEDLINE]
6.

A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers.

Thaler A, Artzi M, Mirelman A, Jacob Y, Helmich RC, van Nuenen BF, Gurevich T, Orr-Urtreger A, Marder K, Bressman S, Bloem BR, Hendler T, Giladi N, Ben Bashat D; LRRK2 Ashkenazi Jewish Consortium.

Mov Disord. 2014 May;29(6):823-7. doi: 10.1002/mds.25827. Epub 2014 Jan 30.

PMID:
24482120
[PubMed - indexed for MEDLINE]
7.

The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Thaler A, Ash E, Gan-Or Z, Orr-Urtreger A, Giladi N.

J Neural Transm. 2009 Nov;116(11):1473-82. doi: 10.1007/s00702-009-0303-0. Review.

PMID:
19756366
[PubMed - indexed for MEDLINE]
8.

G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia.

Pchelina SN, Yakimovskii AF, Ivanova ON, Emelianov AK, Zakharchuk AH, Schwarzman AL.

Mov Disord. 2006 Dec;21(12):2234-6.

PMID:
17044089
[PubMed - indexed for MEDLINE]
9.

The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel.

Hassin-Baer S, Laitman Y, Azizi E, Molchadski I, Galore-Haskel G, Barak F, Cohen OS, Friedman E.

J Neurol. 2009 Mar;256(3):483-7. doi: 10.1007/s00415-009-0117-x. Epub 2009 Mar 24.

PMID:
19412725
[PubMed - indexed for MEDLINE]
10.

LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample.

Goldwurm S, Zini M, Di Fonzo A, De Gaspari D, Siri C, Simons EJ, van Doeselaar M, Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani C, Meucci N, Sacilotto G, Cilia R, Isaias IU, Bonetti A, Sironi F, Ricca S, Oostra BA, Bonifati V, Pezzoli G.

Parkinsonism Relat Disord. 2006 Oct;12(7):410-9. Epub 2006 Jun 5.

PMID:
16750929
[PubMed - indexed for MEDLINE]
11.

The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics.

Gatto EM, Parisi V, Converso DP, Poderoso JJ, Carreras MC, Martí-Massó JF, Paisán-Ruiz C.

Neurosci Lett. 2013 Mar 14;537:1-5. doi: 10.1016/j.neulet.2013.01.011. Epub 2013 Jan 20.

PMID:
23340200
[PubMed - indexed for MEDLINE]
12.

Increased frequency of the LRRK2 G2019S mutation in an elderly Ashkenazi Jewish population is not associated with dementia.

Saunders-Pullman R, Lipton RB, Senthil G, Katz M, Costan-Toth C, Derby C, Bressman S, Verghese J, Ozelius LJ.

Neurosci Lett. 2006 Jul 10;402(1-2):92-6. Epub 2006 Apr 24.

PMID:
16632201
[PubMed - indexed for MEDLINE]
13.

Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease.

Ben Sassi S, Nabli F, Hentati E, Nahdi H, Trabelsi M, Ben Ayed H, Amouri R, Duda JE, Farrer MJ, Hentati F.

Parkinsonism Relat Disord. 2012 Mar;18(3):243-6. doi: 10.1016/j.parkreldis.2011.10.009. Epub 2011 Nov 6.

PMID:
22056842
[PubMed - indexed for MEDLINE]
14.

LRRK2 G2019S founder haplotype in the Chinese population.

Tan EK, Skipper L, Tan L, Liu JJ.

Mov Disord. 2007 Jan;22(1):105-7.

PMID:
17083102
[PubMed - indexed for MEDLINE]
15.

Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.

Mirelman A, Heman T, Yasinovsky K, Thaler A, Gurevich T, Marder K, Bressman S, Bar-Shira A, Orr-Urtreger A, Giladi N, Hausdorff JM; LRRK2 Ashkenazi Jewish Consortium.

Mov Disord. 2013 Oct;28(12):1683-90. doi: 10.1002/mds.25587. Epub 2013 Oct 7.

PMID:
24123150
[PubMed - indexed for MEDLINE]
16.

Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.

Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K.

Neurology. 2006 Nov 28;67(10):1786-91. Epub 2006 Oct 18.

PMID:
17050822
[PubMed - indexed for MEDLINE]
17.

The LRRK2 R1441C mutation is more frequent than G2019S in Parkinson's disease patients from southern Italy.

Criscuolo C, De Rosa A, Guacci A, Simons EJ, Breedveld GJ, Peluso S, Volpe G, Filla A, Oostra BA, Bonifati V, De Michele G.

Mov Disord. 2011 Aug 1;26(9):1733-6. doi: 10.1002/mds.23735. Epub 2011 Apr 29.

PMID:
21538529
[PubMed - indexed for MEDLINE]
18.

Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.

Ishihara L, Warren L, Gibson R, Amouri R, Lesage S, Dürr A, Tazir M, Wszolek ZK, Uitti RJ, Nichols WC, Griffith A, Hattori N, Leppert D, Watts R, Zabetian CP, Foroud TM, Farrer MJ, Brice A, Middleton L, Hentati F.

Arch Neurol. 2006 Sep;63(9):1250-4.

PMID:
16966502
[PubMed - indexed for MEDLINE]
19.

LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease.

Saunders-Pullman R, Barrett MJ, Stanley KM, Luciano MS, Shanker V, Severt L, Hunt A, Raymond D, Ozelius LJ, Bressman SB.

Mov Disord. 2010 Nov 15;25(15):2536-41. doi: 10.1002/mds.23314.

PMID:
20818610
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

LRRK2 G2019S in the North African population: a review.

Benamer HT, de Silva R.

Eur Neurol. 2010;63(6):321-5. doi: 10.1159/000279653. Epub 2010 Apr 23. Review.

PMID:
20413974
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk